PRVB News and Press, Provention Bio Inc. From 01/28/21

Provention Bio (PRVB) posts positive results from a pre-clinical proof-of-concept study for PRV-3279, a DART (bispecific antibody-based molecule) targeting the B cell surface proteins CD32B and CD79B, conducted in a murine model of gene therapy for Pompe disease.In the study PRV-3279 showed r...

Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy - PRV-3279 Murine Surrogate Inhibited the Production of Anti-adenoviral Vector Antibodies in a Mouse Model for Pompe Disease - - R...

Biotech companies have lots of industry-specific risks to navigate. These include potential regulatory roadblocks and negative results from clinical trials. No company wants to discontinue the development of a drug after having spent millions of dollars on the project. But where there is ri...

Intravacc, leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated coxsackievirus B vaccine it developed and manufactured for Provention Bio ([[PRVB]] -0.1%) in less than 36 months, has entered into a first in human Phase...

Provention Bio (PRVB) has priced its public offering of 6.25M common shares at $16.00/share, for expected gross proceeds of $100M.Underwriters' over-allotment is an additional 937.5K shares. Net proceeds will be used for commercialization and development of product candidates; for acquisition...

Provention Bio Announces Pricing of $100 Million Public Offering of Common Stock PR Newswire RED BANK, N.J. , Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immu...

Gainers: Acorda Therapeutics (ACOR) +45%, NuCana (NCNA) +26%, Synlogic (SYBX) +24%, Evoke Pharma (EVOK) +23%, Tiziana Life Sciences (TLSA) +14%.Losers: Zomedica (ZOM) -26%, Forward Pharma (FWP) -15%, Provention Bio (PRVB) -14%, Acutu...

Gainers: [[MTRX]] +24.8%. [[FARM]] +19.1%. [[STIM]] +15.9%. [[EXFO]] +13.1%. [[FSI]] +11.1%.Losers: [[PRTY]] -12.3%. [[QLI]] -9.2%. [[URBN]] -7.8%. [[PRVB]] -7.4%. [[AFMD]] -5.6%. For further details see: MTRX, FARM, PRTY and QLI among after-hours movers

Provention Bio (PRVB) commences an underwritten public offering of 6M shares of its common stock.Underwriters' option to purchase up to an additional 900,000 shares.Company intends to use its net proceeds for (i) pre-commercial activities, potential commercial activities, potential ...

Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in what could be the first of several indicated populations. Provention looks like a ...